Aurigene Services

Aurigene Pharmaceutical Services offers a wide range of discovery chemistry services to biotech, pharmaceutical, agrochemical and specialty chemical companies. This includes synthesis of a library of compounds from a few milligrams to multi-hundred gram scale or differentiated solutions for your discovery ...

Aurigene Pharmaceutical Services offers a wide range of chemical development services for pharmaceutical, agrochemicals, fine chemicals and animal health industry. We support the development of Key Starting Materials (KSM) / Registered Starting Materials (RSM), advance intermediates and APIs from the ...

We provide a wide range of discovery and development services for New Biological Entities (NBEs) from our state-of-the-art facility located in Hyderabad, India. At the core of NBE services is a talented team of scientists experienced in the design and delivery of a range of advanced therapeutic modalities ...

We have access to the manufacturing facilities of Dr. Reddy’s and a network of strategic business partners. Our pharmaceutical drug manufacturing services offer a wide range of manufacturing services from a few kilos to multi tons of cGMP manufacturing of Key Starting Material (KSM) / Registered ...

Aurigene Pharmaceutical Services offers end-to-end formulation development services ranging from early development to clinical supplies for new chemical entities for the pharmaceutical, nutraceutical & animal healthcare industry along with life cycle extension of the products. We have the expertise alo...

Aurigene Pharmaceutical Services Ltd. have opened a biologics facility in Hyderabad, India in a biocluster known as Genome Valley.

Aurigene Pharma announces the construction of a state-of-the art development and manufacturing facility for therapeutic proteins, antibodies, and viral vectors.
As a first step of investment plan, Aurigene is investing $40m in an R&D and pilot scale facility at Genome Valley, a well-known Biotechnology Park in Hyderabad. This facility will meet the process development and clinical supply needs of global biotech companies. The facility is planned to be fully operational in first half of 2024.This complements Aurigene’ s strong foundation in biotherapeutics discovery, contributing to accelerating global R&D-driven (bio)pharma companies’ biologics journey to the market by offering end-to-end and high-quality services for antibodies, proteins, and viral vectors.

Aurigene Pharmaceutical Services is a leading contract research, development and manufacturing organization (CDMO) that provides a range of services. Built on the legacy of accelerating innovation and backed by a vast experience in integrated drug discovery, development and manufacturing services, we provide access to our knowledge, resources, capability and experience, creating shared success for our clients and ultimately patients.

The new offering will support clients with discovery and development services for New Biological Entities (NBE)Hyderabad,

India, November, 11, 2021


Aurigene Pharmaceutical Services Limited, a wholly-owned subsidiary of Dr. Reddy’s expands its existing discovery and development capacities with the inauguration of a biotherapeutics discovery facility in Hyderabad, India. Named New Biological Entity (NBE) Services, this division will complement Aurigene Pharmaceutical Services' offerings to global biopharma companies. NBE offers high-quality, cost-effective services for discovering and developing new advanced biopharmaceuticals such as Antibody Drug Conjugates (ADC), mRNA and CAR-T.


Large molecule therapeutics or biotherapeutics are more advanced drugs that represent a rapidly growing segment of the therapeutics market, and this move further underlines Aurigene’s commitment to serving its global biopharma clients in the areas of these therapeutic technologies.“This expansion was a logical step to leverage our capabilities further and to meet the global demand of domestic and international pharma companies. We are well-positioned through our integrated expertise and resources to support our clients in the discovery and development of biologics and vaccines in a flexible and fast manner,” said Ravi Venkataramanan, CEO of Aurigene.


The expansion complements Aurigene’s existing services for small and large molecule drugs from discovery to launch.


About Aurigene Pharmaceutical Services Limited


Aurigene Pharmaceutical Services is a leading contract research, development and manufacturing organization (CDMO). Built on the legacy of accelerating innovation and backed by a vast experience in drug discovery, development and manufacturing our mission is to relentlessly work for the success of our clients and to build long-term relationships through a holistic approach to accelerate the journey of a molecule from the laboratory to market. By providing access to our resources, knowledge and experience, we create success for our clients and, ultimately, patients. We offer integrated and standalone services for discovery chemistry, discovery biology, development and manufacturing services for clinical phase I-III programs, regulatory submission batches and commercial manufacturing. A differentiating factor is the integrated API and formulations service that spans from key starting material, advanced intermediates, APIs to finished products such as oral solids, sterile products, nasal solutions etc. Our development services in India are complemented by cGMP commercial manufacturing facilities in the UK, Mexico, USA and India.